SEGMENT INFORMATION

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

SEGMENT INFORMATION

NOTE 13 – SEGMENT INFORMATION

The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company’s performance based on its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly, our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.

The CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition, the CODM examines the clinical trials expenses within the research and development operations.

	Year ended December 31,
	2025			2024
Revenues		8,979			7,009
Cost of Revenues:
Material and Labor		5,200			4,698
Other cost of revenues		1,130			805
Total Cost of revenues		6,330			5,503
Research and development (R&D)
Payroll and Benefits		4,052			2,858
Share based compensation		2,559			2,412
Clinical trials		4,488			3,815
Other R&D		3,904			4,549
Total Research and development		15,003			13,634
Selling and marketing (S&M)
Payroll and Benefits		11,346			3,769
Share based compensation		1,888			1,025
Other S&M		3,319			1,275
Total Selling and marketing		16,553			6,069
General and administrative (G&A)
Payroll and Benefits		6,650			4,221
Share based compensation		7,667			6,445
Other G&A		6,390			4,640
Total General and administrative		20,707			15,306
Financial Income, net;		891			1,557
Tax Expenses		63			59
Segment net Loss		(48,786	)		(32,005	)